(Total Views: 409)
Posted On: 06/06/2019 12:15:29 AM
Post# of 154979
Re: Evil Rabbit #3756
I don’t feel like this PR is related to CYDY and is in fact about a separate deal with a different biotech.
“The client is an early stage development company with a high potential early stage asset.” - CYDY is not an early stage company and leronlimab is not an early stage asset
“and will increase to $301 million US when the client obtains approval for the product.” - Isn’t the deal with $1 billion?
“The client is an early stage development company with a high potential early stage asset.” - CYDY is not an early stage company and leronlimab is not an early stage asset
“and will increase to $301 million US when the client obtains approval for the product.” - Isn’t the deal with $1 billion?
(0)
(0)
